A large pharmacy claims-based descriptive analysis of patients with migraine and associated pharmacologic treatment patterns

Neuropsychiatric Disease and Treatment

Volumn 7, Issue 1, 2011, Pages 663-672

  Muzina, David J ^a   Chen, William ^a   Bowlin, Steven J ^a  

^a Medco Health Solutions   (United States)

Author keywords

Comorbidity; Headaches; Migraine preventive therapy; Psychotropics; Triptans

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; ANXIOLYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYPNOTIC AGENT; ILLICIT DRUG; MONOAMINE OXIDASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PROPRANOLOL; PSYCHOTROPIC AGENT; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TIMOLOL; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIPTAN DERIVATIVE; VALPROATE SEMISODIUM;

ADULT; ANXIETY DISORDER; ARTICLE; ATTENTION DEFICIT DISORDER; BIPOLAR DISORDER; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; DEPRESSION; DESCRIPTIVE RESEARCH; DRUG APPROVAL; DRUG USE; FEMALE; FOOD AND DRUG ADMINISTRATION; HEADACHE; HUMAN; INSOMNIA; INTERNATIONAL CLASSIFICATION OF DISEASES; MAJOR CLINICAL STUDY; MALE; MIGRAINE; OFF LABEL DRUG USE; PRESCRIPTION; PREVALENCE; PSYCHOSIS; SUBSTANCE ABUSE; TOBACCO DEPENDENCE; TREATMENT DURATION; TREATMENT INDICATION;

EID: 80955155014     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/ndt.s25463     Document Type: Article

References (39)

1. National Headache Foundation. Categories of Headache. Available from: http://www.headaches.org/press/NHF_Press_Kits/Press_Kits_-_Categories_of_Headache. Accessed July 14, 2010.
2. The global burden of disease: 2004 update. Geneva: World Health Organization, 2008. Available from: http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_full.pdf. Accessed July 14, 2010.
3. Hawkins K, Wang S, Rupnow M. Direct cost burden among insured US employees with migraine. Headache. 2008;48(4):553-563.
4. Hawkins K, Wang S, Rupnow M. Indirect cost burden of migraine in the Unites States. J Occup Environ Med. 2007;49(4):368-374.
5. Silberstein SD; for the US Headache Consortium. Practice parameter: Evidence-based guidelines for migraine headache. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000;55(6):754-762.
6. Lipton RB, Bigal ME, Diamond M, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68(5): 343-349.
7. Lafata JE, Moon C, Leotta C, Kolodner K, Poisson L, Lipton RB. The medical care utilization and costs associated with migraine headache. J Gen Intern Med. 2004;19(10):1005-1012.
8. National Center for Health Statistics. International Classification of Diseases, Ninth Revision. Atlanta, GA: CDC/National Center for Health Statistics; 2009.
9. Von Korff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol. 1992;45(2):197-203.
10. Lipton RB, Scher AI, Kolodner K, Liberman J, Steiner TJ, Stewart WF. Migraine in the United States: Epidemiology and patterns of health care use. Neurology. 2002;58(6):885-894.
11. Lipton RB, Diamond S, Reed M, Diamond ML, Stewart WF. Migraine diagnosis and treatment: results from the American Migraine Study II. Headache. 2001;41(7):638-645.
12. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed ML. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache. 2001;41:646-657.
13. Breslau N, Davis GC. Migraine, physical health and psychiatric disorder: A prospective epidemiologic study in young adults. J Psychiatr Res. 1993;27(2):211-221.
14. Tepper SJ, Tepper DE. Breaking the cycle of medication overuse headache. Cleveland Clinic Journal of Medicine. 2010;77(4):236-242.
15. Ho TW, Rodgers A, Bigal ME. Impact of recent prior opioid use on rizatriptan efficacy. A post hoc pooled analysis. Headache. 2009; 49(3):395-403.
16. Wilkinson SM, Becker WJ, Heine JA. Opiate use to control bowel motility may induce chronic daily headache in patients with migraine. Headache. 2001;41(3):303-309.
17. Bahra A, Walsh M, Menon S, Goadsby PJ. Does chronic daily headache arise de novo in association with regular use of analgesics? Headache. 2003;43(3):179-190.
18. Bigal ME, Serrano D, Buse D, Scher AI, Stewart WF, Lipton RB. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache. 2008; 48(8):1157-1168.
19. Bigal ME, Lipton RB. Excessive acute migraine medication use and migraine progression. Neurology. 2008;71(22):1821-1828.
20. Andermann E, Andermann F. Migraine-epilepsy relationships: epidemiological and genetic aspects. In: Andermann F, Lugaresi E, editors. Migraine and Epilepsy. Boston, MA: Butterworth-Heinemann; 1987:281-291.
21. Haddad PM, Dursun SM. Neurological complications of psychiatric drugs. Hum Psychopharmacol. 2008;23 Suppl 1:15-26.
22. Walter SD. Berkson's bias and its control in epidemiologic studies. J Chronic Dis. 1980;33(11-12):721-725.
23. Agostoni E, Aliprandi A. Migraine and hypertension. Neurological Sciences. 2008;29 Suppl 1:37-39.
24. Barbanti P, Aurilia C, Egeo G, Fofi L. Hypertension as a risk factor for migraine chronification. Neurol Sci. 2010;31 Suppl 1:41-43.
25. Burn WK, Machin D, Waters WE. Prevalence of migraine in patients with diabetes. Br Med J (Clin Res Ed). 1984;289(6458):1579-1580.
26. Dandona P, James IM, Beckett AG. Prevalence of migraine in patients with diabetes. Br Med J (Clin Res Ed). 1985;290(6466):467-468.
27. Diamond S, Bigal ME, Silberstein S, Loder E, Reed M, Lipton RB. Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American Migraine Prevalence and Prevention study. Headache. 2007;47(3):355-363.
28. Scher AI, Stewart WF, Ricci JA, Lipton RB. Factors associated with the onset and remission of chronic daily headache in a population-based study. Pain. 2003;106(1-2):81-89.
29. Bigal ME, Rapoport AM, Lipton RB, Tepper SJ, Sheftell FD. Assessment of migraine disability using the migraine disability assessment (MIDAS) questionnaire: a comparison of chronic migraine with episodic migraine. Headache. 2003;43(4):336-342.
30. Dodick DW. Clinical practice. Chronic daily headache. N Engl J Med. 2006;354(2):158-165.
31. Verri AP, Proietti Cecchini A, Galli C, Granella F, Sandrini G, Nappi G. Psychiatric comorbidity in chronic daily headache. Cephalalgia. 1998; 18 Suppl 21:45-49.
32. Peres MF, Young WB, Kaup AO, Zukerman E, Silberstein SD. Fibromyalgia is common in patients with transformed migraine. Neurology. 2001;57(7):1326-1328.
33. Pompili M, Serafini G, Di Cosimo D, et al. Psychiatric comorbidity and suicide risk in patients with chronic migraine. Neuropsychiatr Dis Treat. 2010;6:81-91.
34. Silberstein SD, Winner PK, Chmiel JJ. Migraine preventive medication reduces resource utilization. Headache. 2003;43(3):171-178.
35. Mei D, Ferraro D, Zelano G, et al. Topiramate and triptans revert chronic migraine with medication overuse to episodic migraine. Clin Neuropharmacol. 2006;29(5):269-275.
36. Feliu AL, Rupnow MF, Blount A, Boccuzzi SJ, Vermilyea J. Resource use associated with topiramate in migraine prophylaxis. Am J Health Syst Pharm. 2007;64(14):1483-1491.
37. Silberstein SD, Feliu AL, Rupnow MF, Blount AC, Boccuzzi SJ. Topiramate in migraine prophylaxis: long-term impact on resource utilization and cost. Headache. 2007;47(4):500-510.
38. Bigal ME, Buse DC, Chen YT, et al. Rates and predictors of starting a triptan: results from the American Migraine Prevalence and Prevention Study. Headache. 2010; 50(9):1440-1448.
39. Pietrini P, Guazzelli M. Life events in the course of chronic diseases: A psychological myth or a psycho-neuro-biochemical loop? Clin Exp Rheumatol. 1997;15(2):125-128.